drugset / Trial / NCT04056611

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

NCT04056611

Phase 2 Terminated 3 enrolled Janssen Sciences Ireland UC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients with RSV upper RTI.

Timeline

Start
2019-12-26
Primary completion
2022-02-04
Completion
2022-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilematovir Other / unclassified 125 mg Oral
Subject Rilematovir Other / unclassified 250 mg Oral